Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Dual-action obesity drug rewires brain circuits for appetite
A two-in-one drug that modulates neural pathways involved in appetite and reward might prove to be more effective and longer lasting than current weight-loss drugs on the market.
Darleen Sandoval is in the Section of Nutrition, Department of Pediatrics and Division of Endocrinology, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA.
The brain is responsible for regulating how much is eaten and how many calories are burned throughout the day, but in obesity, this balance is disrupted, causing weight gain. Until a few years ago, the most effective strategy for sustained weight loss was surgery. Now, the popular anti-obesity drugs semaglutide (sold under the names Ozempic and Wegovy) and tirzepatide (sold as Mounjaro) are becoming almost as effective as surgery at evoking weight loss. These drugs are based on a peptide made in the gut called GLP-1, and they act on GLP-1 receptors in the brain to suppress eating. However, these medications are costly, in high demand and produce variable results — driving the need for more obesity treatment options. Writing in Nature, Petersen et al.1 describe how combining a GLP-1 receptor activator with another drug that acts on the brain could be an effective treatment for obesity.